After six years of existence and raising more than $20 million, Personal Genome Diagnostics has its first full-time CEO.
Douglas Ward will head the Canton-based Johns Hopkins spinout and sit on its board, the company announced Monday.
Ward has worked in medical diagnostics for 25 years, most recently serving as Vice President of Companion Diagnostics at Ventana Medical Systems. He has also worked at GE Healthcare and Bayer Healthcare.
Founded in 2010 by Hopkins cancer researchers Victor Velculescu and Luis Diaz, Personal Genome Diagnostics specializes in technology to assist cancer genome testing. The company closed a $21.4 million Series A led be NEA in 2015.
Personal Genome Diagnostics previously did not have a CEO. A spokeswoman said Ward is “expected to build on the company’s record of strong growth and provide experienced leadership for the further development of key product lines.”
Before you go...
To keep our site paywall-free, we’re launching a campaign to raise $25,000 by the end of the year. We believe information about entrepreneurs and tech should be accessible to everyone and your support helps make that happen, because journalism costs money.
Can we count on you? Your contribution to the Technical.ly Journalism Fund is tax-deductible.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
The looming TikTok ban doesn’t strike financial fear into the hearts of creators — it’s community they’re worried about
Protests highlight Maryland’s ties to Israeli tech and defense systems
Congress votes to reauthorize the EDA, marking a historic bipartisan effort to invest in innovation and job creation
